Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

FIGO statement: Fertility preservation.

FIGO statement: Fertility preservation. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Henry, L., Berek, J. S., Diaz, I., Feldberg, D., Mocanu, E., Niederberger, C. C., Ohlander, S., Purandare, N., Rosenwaks, Z., Tulandi, T., Wasson, M., Wilailak, S., Malhotra, J. 2023

Abstract

Fertility preservation is a growing field in reproductive medicine that may raise ethical questions. Preservation of fertility must be discussed with the patient if gonadotoxic treatment is required, whether in the case of benign or malignant pathology, or in the management of transgender identity. As a result, surgery or chemotherapy that has fewer adverse impacts on fertility should be proposed if this does not alter the prognosis of the disease. If the risk of infertility persists, then fertility cryopreservation should be proposed for children and adults of reproductive age. Sperm, oocytes, and gonadal tissue can be cryopreserved for many years. FIGO wishes to emphasize the importance of fertility preservation in the medical and surgical management of patients, and the importance of a specialized, multidisciplinary approach.

View details for DOI 10.1002/ijgo.15187

View details for PubMedID 37807831